CClinicalTrials.gg
CompletedNCT00660127Updated Mar 16, 2017

The Effect of Visual Stimuli on Itch Perception Intensity in Healthy and Atopic Dermatitis Patients

An observational study in Atopic Dermatitis, sponsored by Wake Forest University Health Sciences. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-16.

Sponsored by Wake Forest University Health Sciences · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
25
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this research study is to assess whether seeing other people itch affects itch perception in patients with atopic dermatitis and healthy subjects.

Read the detailed description

The objectives of this study are to quantitatively assess the effect of visual stimuli on perception of itch and to assess if visual stimuli affect individuals with atopic dermatitis differently than healthy people.

02

Conditions studied

03

In context

Dermatitis, Atopic

1,419 studies on the registry are indexed under Dermatitis, Atopic; 258 are open to participants now.

This study's enrollment of 25 is below the median of 150 across 237 observational studies indexed under Dermatitis, Atopic.

Browse Dermatitis, Atopic studies →

Lead sponsor

Wake Forest University Health Sciences is the lead sponsor of 1,320 studies on the registry; 199 are open to participants now.

Of its 323 completed or terminated interventional studies of FDA-regulated products, 243 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

general community population

Inclusion criteria

  • Adult men and women who are between 18 and 65 years of age
  • Diagnosis of moderate to severe atopic dermatitis including involvement of the forearm confirmed by published consensus diagnostic criteria35 (except for healthy control subjects). Severity of AD will be based on an investigator's global assessment score (IGA).
  • Subjects must be in general good health with no other skin disease, disease state or physical condition which would impair evaluation of their skin or which would increase their health risk by study participation
  • Women of child bearing potential will be required to have a negative pregnancy test in order to enroll in the study and will be required to maintain adequate birth control throughout the study.
  • All subjects in Groups 1 and 3 will be required to cease use of oral antihistamines for a period of one week prior to and during the study visit.
  • Subjects in Groups 1 and 3 must cease using topical agents on the forearm where experimentation is going to be performed at least 1 week prior. Topical agents can be used in all other parts of the body.
  • Baseline COVAS ratings of more than 9/100 after histamine iontophoresis at the screening visit

Exclusion criteria

Exclusion Criteria:

  • Adults over age 65
  • Children less than 18 years of age
  • Unable to complete the required measures
  • Currently enrolled in any investigational study in which the subject is receiving any type of drug, biologic, or non-drug therapy and subjects undergoing treatment with another investigational drug or approved therapy for investigational use within 28 days prior to study participation
  • Consumption of more than 4 caffeinated beverages per day
  • Current treatment with oral lipophilic beta blockers, opioids, glucocorticoids, theophylline, antihistamines or other medications known to interfere with itch perception or heart rate variability as determined by the investigators
  • Uncontrolled asthma or COPD
  • Uncontrolled thyroid disease
  • Poorly controlled diabetes mellitus
  • Poorly compensated congestive heart failure
  • Use of illicit drugs
  • History of chronic urticaria
  • History of anaphylactic shock
  • History of neuropathy causing disease such as diabetes and uremia
  • Allergy to histamine
  • Blindness
  • Baseline COVAS ratings of less than 9/100 after histamine iontophoresis at the screening visit
  • Subject participation in more than one group.
  • Positive pregnancy test
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
25 participants (actual)
06

Study locations

1 site
  • Wake Forest University Health Sciences Dermatology
    Winston Salem, North Carolina 27157, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00660127
Lead sponsor
Wake Forest University Health Sciences
Responsible party
Sponsor
First posted
Apr 17, 2008
Start date
Oct 2007
Primary completion
Dec 2009
Completion
Dec 2009
Last update
Mar 16, 2017

Study contacts

Gil Yosipovitch, MD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion